By Steven Reinberg

HealthDay Columnist

THURSDAY, May 28, 2015 (HealthDay News) — The diabetes medicate metformin was connected to a lower risk of developing the eye condition glaucoma in a new think about.

People who took the foremost metformin during the 10-year consider period had a 25 percent reduced chance of glaucoma compared with individuals not taking the medicate, analysts found.

“Glaucoma could be a leading cause of visual deficiency worldwide and classic open-angle glaucoma develops in late center age or late age. So we hypothesized that a drug that imitates caloric restriction, such as metformin, might diminish the risk of glaucoma,” said lead researcher Julia Richards, a teacher of ophthalmology and visual sciences at the College of Michigan in Ann Arbor.

Exactly how metformin might diminish the chance of glaucoma isn’t known, the researchers said. And, while this consider found an association between metformin utilize and lower glaucoma risk, it wasn’t planned to demonstrate a cause-and-effect relationship.

Dr. Mark Fromer, an ophthalmologist at Lenox Hill Hospital in Unused York City, explained that glaucoma is caused by too much fluid in the eye, when liquid doesn’t drain enough, or when the blood vessels within the optic nerve are harmed. “Some way or another metformin is influencing one of those conditions,” he said.

Fromer pointed out that although the results of this consider are impressive, utilizing metformin to anticipate or treat glaucoma in non-diabetic patients is risky. Metformin could drop blood sugar too low in people without diabetes, he said.

“People without diabetes should not be taking metformin,” he said. “In the event that not monitored carefully by a specialist, it can have significant consequences,” said Fromer, who was not included with the think about.

Richards, in any case, said that it may be possible to utilize metformin as a treatment for glaucoma even in individuals without diabetes.

“But since this study was exhausted a diabetic populace, the conclusions are currently constrained to this populace,” she said. “Encourage work, such as a clinical trial, would be required to tell if this may be extended to non-diabetic populaces or used to avoid progression of glaucoma in those who already have the illness,” Richards said.

The study was distributed online May 28 in JAMA Ophthalmology.

For the think about, Richards and colleagues collected 10 years of data on more than 150,000 individuals with diabetes. All were 40 or more seasoned at the begin of the consider. The investigators found that 4 percent of the participants created glaucoma.

The researchers said that individuals taking the most elevated amount of metformin (more than 1,110 grams in two years) had a 25 percent reduced risk of creating glaucoma compared with those not taking the medicate.

For each 1-gram increase in metformin taken, the hazard was diminished by 0.16 percent. The researchers estimated that taking a standard dosage of metformin (2 grams per day) for two years would diminish the hazard for glaucoma by 21 percent.

This hazard lessening was seen indeed after bookkeeping for lower blood sugar levels, the ponder creators said. Other diabetes drugs were not associated with diminished risk of glaucoma, they added.